First-in-human Single Ascending Dose Study of LNA043 in Patients Scheduled for Total Knee Replacement
Status:
Completed
Trial end date:
2018-03-06
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the safety and tolerability of ascending single doses of
LNA043 given intra-articularly into the human knee joint prior to its removal at total knee
replacement surgery. In addition, this will help to establish the presence of LNA043 within
the articular cartilage, assess pharmacokinetics and immunogenicity, and will allow
exploration of biomarkers of hyaline cartilage repair.